Deferoxamine (DFO) and other iron chelators are clinically used for cancer and stroke. They may also be useful for Alzheimer's disease (AD) to diminish iron from microbleeds. DFO may also stimulate antioxidant membrane repair which is impaired during AD. DFO and other chelators do enter the brain despite some contrary reports.
Objective
Low dose, oral DFO was given in lab chow to wildtype (WT) C57BL/6 mice to evaluate potential impact on iron levels, iron-signaling and storage proteins, and amyloid-β protein precursor (AβPP) and processing enzymes. Young WT mice do not have microbleeds or disrupted blood-brain barrier of AD mice.
Methods
Iron was measured by MRI and chemically after two weeks of dietary DFO. Cerebral cortex was examined for changes in iron metabolism, antioxidant signaling, and AβPP processing by western blot.
Results
DFO decreased brain iron 18% (p < 0.01) estimated by R2 MRI and decreased seven major proteins that mediate iron metabolism by at least 25%. The iron storage proteins ferritin light and heavy chain decreased by at least 30%. AβPP and secretase enzymes also decreased by 30%.
Conclusions
WT mice respond to DFO with decreased AβPP, amyloid processing enzymes, and antioxidant repair. Potential DFO treatment for early-stage AD by DFO should consider the benefits of lowered AβPP and secretase enzymes.
ButterfieldDALauderbackCM. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med2002; 32: 1050–1060.
2.
MontineTJNeelyMDQuinnJF, et al.Lipid peroxidation in aging brain and Alzheimer’s disease. Free Radic Biol Med2002; 33: 620–626.
3.
ChenLDarNJNaR, et al.Enhanced defense against ferroptosis ameliorates cognitive impairment and reduces neurodegeneration in 5xFAD mice. Free Radic Biol Med2022; 180: 1–12.
4.
ThorwaldMAGodoy-LugoJAGarciaG, et al.Iron associated lipid peroxidation in Alzheimer’s disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice. bioRxiv2023. doi: https://doi.org/10.1101/2023.03.28.534324. [Preprint]. Posted June 13, 2024.
5.
CacciottoloMMorganTEFinchCE. Age, sex, and cerebral microbleeds in EFAD Alzheimer disease mice. Neurobiol Aging2021; 103: 42–51.
6.
van BergenJMGLiXHuaJ, et al.Colocalization of cerebral iron with amyloid beta in mild cognitive impairment. Sci Rep2016; 6: 35514.
7.
AytonSPortburySKalinowskiP, et al.Regional brain iron associated with deterioration in Alzheimer’s disease: a large cohort study and theoretical significance. Alzheimers Dement2021; 17: 1244–1256.
8.
AshrafAJeandriensJParkesHG, et al.Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: evidence of ferroptosis. Redox Biol2020; 32: 101494.
9.
HernandezPJohnsonCA. Deferoxamine for aluminum toxicity in dialysis patients. ANNA J1990; 17: 224–228.
10.
FarkasECsókaHMiceraG, et al.Copper(II), nickel(II), zinc(II), and molybdenum(VI) complexes of desferrioxamine B in aqueous solution. J Inorg Biochem1997; 65: 281–286.
11.
FarrACXiongMP. Challenges and opportunities of deferoxamine delivery for treatment of Alzheimer’s disease, Parkinson’s disease, and intracerebral hemorrhage. Mol Pharm2021; 18: 593–609.
12.
OlivieriNFBrittenhamGM. Iron-chelating therapy and the treatment of thalassemia. Blood1997; 89: 739–761.
13.
KangHHanMXueJ, et al.Renal clearable nanochelators for iron overload therapy. Nat Commun2019; 10: 5134.
14.
Crapper McLachlanDRDaltonAJKruckTP, et al.Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet1991; 337: 1304–1308.
15.
FujisawaKTakamiTMatsumotoT, et al.An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells. Cancer Metab2022; 10: 8.
16.
KeberleH. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci1964; 119: 758–768.
17.
WardRJDexterDFlorenceA, et al.Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism. Biochem Pharmacol1995; 49: 1821–1826.
18.
ShacharDBKahanaNKampelV, et al.Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology2004; 46: 254–263.
19.
PalmerCRobertsRL. Deferoxamine starch conjugate provides partial protection from hypoxic-ischemic brain injury in neonatal rats † 1749. Pediatr Res1997; 41: 294.
20.
HurnPDKoehlerRCBlizzardKK, et al.Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. Stroke1995; 26: 688–694; discussion 694–695.
21.
Di NicolaMBarteselliGDell’ArtiL, et al.Functional and structural abnormalities in deferoxamine retinopathy: a review of the literature. Biomed Res Int2015; 2015: 249617.
22.
BayanzayKAlzoebieL. Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. J Blood Med2016; 7: 159–169.
23.
BrittenhamGM. Iron-chelating therapy for transfusional iron overload. N Engl J Med2011; 364: 146–156.
24.
FineJMRennerDBForsbergAC, et al.Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. Neurosci Lett2015; 584: 362–367.
25.
HansonLRFineJMRennerDB, et al.Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. Drug Deliv Transl Res2012; 2: 160–168.
26.
ZhangYHeM. Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in APP/PS1 mice. Brain Res2017; 1677: 86–92.
27.
FineJMKosyakovskyJBaillargeonAM, et al.Intranasal deferoxamine can improve memory in healthy C57 mice, suggesting a partially non-disease-specific pathway of functional neurologic improvement. Brain Behav2020; 10: e01536.
28.
GuoZLinJSunK, et al.Deferoxamine alleviates osteoarthritis by inhibiting chondrocyte ferroptosis and activating the Nrf2 pathway. Front Pharmacol2022; 13: 791376.
29.
InoueHHanawaNKatsumataS-I, et al.Iron deficiency induces autophagy and activates Nrf2 signal through modulating p62/SQSTM. Biomed Res2017; 38: 343–350.
30.
WinklerEASengilloJDSagareAP, et al.Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A2014; 111: E1035–E1042.
31.
FebbraroFAndersenKJSanchez-GuajardoV, et al.Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson’s model. Exp Neurol2013; 247: 45–58.
32.
BarnesSRNgTSCSanta-MariaN, et al.ROCKETSHIP: a flexible and modular software tool for the planning, processing and analysis of dynamic MRI studies. BMC Medical Imaging2015; 15: 19.
33.
BaumingerERHarrisonPMHechelD, et al.Iron (III) can be transferred between ferritin molecules. Proc Biol Sci1991; 244: 211–217.
34.
ManciasJDWangXGygiSP, et al.Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature2014; 509: 105–109.
35.
RogersJTRandallJDCahillCM, et al.An iron-responsive element type II in the 5’-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem2002; 277: 45518–45528.
36.
IgarashiKHoshinoHMutoA, et al.Multivalent DNA binding complex generated by small maf and Bach1 as a possible biochemical basis for β-globin locus control region complex. J Biol Chem1998; 273: 11783–11790.
37.
VenugopalRJaiswalAK. Nrf1 and Nrf2 positively and c-fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A1996; 93: 14960–14965.
38.
ChenYShertzerHGSchneiderSN, et al.Glutamate cysteine ligase catalysis: dependence on ATP and modifier subunit for regulation of tissue glutathione levels. J Biol Chem2005; 280: 33766–33774.
39.
ThomasJPGeigerPGMaiorinoM, et al.Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. Biochim Biophys Acta1990; 1045: 252–260.
40.
FisherAB. Peroxiredoxin 6 in the repair of peroxidized cell membranes and cell signaling. Arch Biochem Biophys2017; 617: 68–83.
41.
CastroJPJungTGruneT, et al.4-Hydroxynonenal (HNE) modified proteins in metabolic diseases. Free Radic Biol Med2017; 111: 309–315.
42.
DuKOhSHDuttaRK, et al.Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells but exacerbates chronic liver injury. Liver Int2021; 41: 2214–2227.
43.
TangDChenXKangR, et al.Ferroptosis: molecular mechanisms and health implications. Cell Res2021; 31: 107–125.
44.
MontagneANikolakopoulouAMHuuskonenMT, et al.APOE4 Accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β. Nat Aging2021; 1: 506–520.
45.
BellRDWinklerEASinghI, et al.Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature2012; 485: 512–516.
46.
HuhHParkTYSeoH, et al.A local difference in blood-brain barrier permeability in the caudate putamen and thalamus of a rat brain induced by focused ultrasound. Sci Rep2020; 10: 19286.
47.
WinklerEASengilloJDBellRD, et al.Blood–spinal cord barrier pericyte reductions contribute to increased capillary permeability. J Cereb Blood Flow Metab2012; 32: 1841–1852.
48.
ChangRCastilloJZambonAC, et al.Brain endothelial erythrophagocytosis and hemoglobin transmigration across brain endothelium: implications for pathogenesis of cerebral microbleeds. Front Cell Neurosci2018; 12: 279.
49.
O’ConnellMJWardRJBaumH, et al.The role of iron in ferritin- and haemosiderin-mediated lipid peroxidation in liposomes. Biochem J1985; 229: 135–139.
50.
LitwackG. Chapter 19 - Micronutrients (metals and iodine). In: LitwackG (ed.) Human biochemistry. 2nd ed. Boston: Academic Press, 2021, pp. 647–701.
51.
JanawayBMSimpsonJEHoggardN, et al.Brain haemosiderin in older people: pathological evidence for an ischaemic origin of magnetic resonance imaging (MRI) microbleeds. Neuropathol Appl Neurobiol2014; 40: 258–269.
52.
KhanMAMohammadTMalikA, et al.Iron response elements (IREs)-mRNA of Alzheimer’s amyloid precursor protein binding to iron regulatory protein (IRP1): a combined molecular docking and spectroscopic approach. Sci Rep2023; 13: 5073.
53.
DuceJATsatsanisACaterMA, et al.Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell2010; 142: 857–867.
54.
LinRChenXLiW, et al.Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: blockage by curcumin. Neurosci Lett2008; 440: 344–347.
55.
GongLTianXZhouJ, et al.Iron dyshomeostasis induces binding of APP to BACE1 for amyloid pathology, and impairs APP/Fpn1 complex in microglia: implication in pathogenesis of cerebral microbleeds. Cell Transplant2019; 28: 1009–1017.
56.
MarasJSDasSSharmaS, et al.Iron-overload triggers ADAM-17 mediated inflammation in severe alcoholic hepatitis. Sci Rep2018; 8: 10264.
57.
XuHPerreauVMDentKA, et al.Iron regulates apolipoprotein E expression and secretion in neurons and astrocytes. J Alzheimers Dis2016; 51: 471–487.
58.
MurakamiHTakanagaHMatsuoH, et al.Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am J Physiol Heart Circ Physiol2000; 279: H1022–H1028.
59.
SyvänenSLindheOPalnerM, et al.Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos2009; 37: 635–643.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
